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Continuous positive airway pressure (CPAP) is the treatment of choice for obstructive sleep apnoea syndrome
(OSAS), but many patients find this treatment intolerable. The aim of this study was to characterize patients who
were unable to tolerate CPAP treatment (non-complaint) as opposed to those who continued using CPAP
(complaint).
A case-control study was performed in which the cases comprised of 40 patients who had been started on CPAP
treatment but had found the treatment unacceptable and had ceased to use CPAP. The controls comprised of 63
patients with OSAS who had been prescribed CPAP and were still using it (follow-up period 18 months to 10 yr).
The patients who stopped CPAP treatment had a higher mean age, had more frequently undergone
uvulopalatopharyngoplasty (UPPP) and had a lower mean oxygen desaturation index (ODI) than patients who
continued using CPAP. ODI was an independent negative predictor of non-compliance (OR5units=06(04–08),
P5001). The two most common reasons for non-compliance were problems in the nose or pharynx and lack of
subjective eect by the treatment. High age was an independent risk factor for non-compliance because of problems
in the nose or pharynx (OR10 years=28(13–61), P5001), while having undergone UPPP was a risk factor for non-
compliance because of lack of eect (OR=45 (11–191), P5005).
In conclusion, patients with less severe OSAS are more likely to discontinue CPAP treatment. The risk of
experiencing nasal and pharyngeal side-eects of such severity that the patient stops using CPAP increases with age
and patients who have undergone UPPP are less likely to experience a clinical improvement after being started on
CPAP therapy.
RESPIR. MED. (2000) 94, 145±149 # 2000 HARCOURT PUBLISHERS LTDIntroduction
Treatment with continuous positive airway pressure
(CPAP) is usually regarded as the treatment of choice for
obstructive sleep apnoea (OSAS). CPAP treatment has
been shown to improve daytime sleepiness (1,2) and
daytime performance (1,2) to reduce the risk of trac
accidents in patients with OSAS (3) and it has also been
indicated that it reduces mortality in patients with severe
OSAS (4). One drawback when it comes to CPAP
treatment, however, is that many patients find this
treatment unacceptable (1,5,6) and it has been estimated
that more than 50% of patients who are selected for CPAP
therapy stop the treatment or only use it for part of the
night (7).Received 9 June 1999 and accepted in revised form 22 September
1999.
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0954-6111/00/020145+05 $35?00/0The aim of this study was to characterize the patients
who were unable to tolerate CPAP treatment as opposed to
those who continued using CPAP over a long period of
time.
Materials and methods
In this investigation, a case-control study was performed.
PATIENTS
The cases comprised of all the patients with OSAS at our
department who had been started on CPAP treatment
during the time period 1986–95 but had found the
treatment unacceptable and ceased to use CPAP after a
time interval of 3 months to 3 years (‘non-complaint’,
n=40).
The controls comprised patients with OSAS in our
department who had been prescribed CPAP, who were still
using it and had been followed for at least 18 months (18
months to 10 yr) (‘compliant’ n=63).# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Characteristics of patients that continued using
continuous positive airway pressure (CPAP) and patients
who quitted the treatment [(%) and mean (SD)]
Compliant
(n=63)
Non-compliant
(n=40)
Women 10 15
Age (years) 53 (9) 58 (10) *
Current smokers 29 24
BMI (kg m2) 32 (5) 29 (4) ***
UPPP 16 36 *
Hypertension 39 50
Cardiac disease 22 43
Diabetes 14 14
Airway disease 29 20
Psychiatric disorder 8 12
*P5005; ***P50001.
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because of verified or suspected OSAS. The diagnosis was
confirmed by a full-night recording with oximetry and an
airflow thermistor. Some of the patients (n=23) had
undergone uvulopalatopharyngoplasty (UPPP) before
being referred to our department for CPAP treatment.
CLINICAL INVESTIGATION
Before the introduction of the CPAP treatment, all the
patients were seen by a physician for a clinical examination.
The weight and height of the patient were recorded and the
body mass index (BMI) was calculated.
The patients classified their symptoms on a five-point
scale in a multiple choice format (8,9). In the subsequent
analyses of excessive daytime sleepiness, scores of 4 and 5
(‘severe’ and ‘very severe’) were regarded as representing
major complaints, a score of 3 represented a moderate
complaint and scores of 1 and 2 no complaints. Scores of 4
and 5 (‘often and very often’) for snoring were regarded as
habitual, a score of 3 (‘sometimes’) as occasional and scores
of 1 and 2 as no complaints.
NIGHTLY OXIMETRIC INVESTIGATION
The patients were investigated on three consecutive nights
with oximetry (OXI3, Radiometer, Copenhagen, Den-
mark). This was done in hospital under the supervision of
a nurse, who also noted regularly whether or not the patient
was asleep. The oximetric curves were evaluated manually,
with calculations of the number of desaturations of at least
4% points compared with baseline during the night divided
by the time spent in bed, thereby producing the oxygen
desaturation index (ODI). The lowest oxygen saturation
during the night was recorded. No CPAP was used on the
first night. The second night was used for pressure titration
and, on the third night, the patients were treated with the
pressure that was found to be optimal during the second
night.
All but two patients were prescribed conventional fixed
pressure CPAP units, the most common being Tranquillity
Plus (Health Dyne, Pittsburg, U.S.A.) (n=59) and REM
Plus (Sefam, Nancy, France) (n=20). Two patients were
prescribed auto-adjusting CPAP (Morphee Plus, Pierre
Medical, Nancy, France). No humidifiers were prescribed
to any of the patients.
FOLLOW-UP
After the introduction of CPAP, all the patients were
followed up with a clinical investigation and oximetry for
one night after 3 and 12 months. A specially trained nurse
who saw the patients at least once a year then followed-up
patients in whom the CPAP treatment was judged to be
working satisfactorily. In 24 of the patients, the prescribed
CPAP unit was subsequently (3 months–7 y) changed. The
units that were switched to were another fixed pressure
CPAP in 19 patients, an auto-adjusting CPAP in four
patients and bilevel positive airway pressure (BiPAP-S,Respironics, Murrysville, Pensylvanian, U.S.A.) in one
patient.
Patients who returned their units were also seen by the
same nurse who registered the reason why the patient did
not find the CPAP treatment tolerable and referred and
patient to a physician for a decision on alternative
treatment.
STATISTICS
The statistical analysis was performed using the Statistica
50 software package (StatSoft Inc, Tulsa, OK, U.S.A.).
The paired t-test, Mann–Whitney U-test and 2-test were
used to compare compliant and non-compliant patients.
Logistic regression was used for multivariate analysis. The
minimal statistical significance level for all analyses was
P5005. Mean values are presented as the mean (SD) and
odds ratios as OR (95% CI).
Results
The patients who discontinued the CPAP treatment had a
higher mean age, a lower BMI and had more frequently
undergone UPPP compared with patients who continued
using CPAP (Table 1).
For the whole group, the mean ODI before CPAP
treatment was 30 (19). Patients who continued using CPAP
had a higher ODI (Fig. 1) and a lower minimal oxygen
saturation (69(15) vs. 78(8)%) (P50001) before treatment
than non-complaint patients. The group that continued
using CPAP required a slightly higher pressure (9(3) vs. 8(3)
cm H2O, P5005) than the patients who discontinued the
treatment, but no dierence was found in ODI or minimal
oxygen saturation between the two patient groups after
pressure titration.
FIG 1. Box plot indicating median, inter-quartile deviation
and range for oxygen desaturation index (ODI) before
continuous positive airway pressure (CPAP) and with
CPAP after pressure titration in complaint (C) and non-
complaint (NC) patients (***P50001).
TABLE 2. Risk factors for discontinuing continuous positive
airway pressure (CPAP) treatment because of problems
from the nose and pharynx and lack of subjective eect
after adjustment for all variables in the table. (OR=odds
ratio, CI=confidence interval)
Nose or pharynx Lack of eect
OR (95%CI) OR (95%CI)
Age{ 28 (13–61)** 15 (07–28)
BMI{ 07 (03–17) 05 (02–13)
UPPP 14 (03–60) 45 (11–191)*
ODI{ 09 (06–13) 06 (03–11)
{OR10 years;
{OR5 units. *P=005; **P5001
FIG 2. Reported snoring and daytime sleepiness before
treatment in compliant (C) and non-compliant (NC)
patients. Filled boxes represent habitual/major
compliants and open boxes occasional/moderate
complaints (*P5005).
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reported snoring and daytime sleepiness before starting
treatment than patients who stopped the treatment (Fig. 2).
There was a non-significant trend that patients that had
undergone UPPP had a lower ODI before treatment than
patients who had not undergone UPPP (25(17) vs. 32(20))
(P=015). In the non-complaint group, no dierence in
ODI was found between those who had undergone UPPP
and those that had not [20(12) vs. 9(13)].
ODI was an independent negative predictor for disconti-
nuing the CPAP treatment after adjustment for age, gender,
BMI and pre-treatment UPPP by means of logistic
regression (OR5units=06(04–08), P5001).
The two most common reasons for discontinuing CPAP
treatment were problems from the nose or pharynx (n=14)
and a lack of subjective eect from the treatment (n=14).
Eight patients stated that the mask gave them a feeling of
panic or claustrophobia, five patients said that they were
disturbed by the noise of the CPAP unit and three patients
had problems with leakage from the mask.
High age was an independent risk factor for discontinu-
ing the treatment because of problems from the nose or
pharynx, while having undergone UPPP was a risk factor
for discontinuing the CPAP treatment because of lack of
eect (Table 2).
Discussion
The main finding in this study is that patients with less
severe OSAS are more likely to find CPAP treatmentintolerable. In our investigation, side-eects from the nose
or pharynx and lack of subjective eect were the two most
prevalent reasons for discontinuing the treatment. The risk
of discontinuing the treatment because of nasal or
pharyngeal side eects increased with age, while patients
who had undergone UPPP were more likely to discontinue
the treatment because of lack of eect.
This investigation was conducted in a clinical setting and
there are some clear limitations to our study. We have no
data on the actual use of CPAP in the group who continued
with the treatment. Some of the patients who were defined
as compliant may therefore be using CPAP only intermit-
tently. This may lead to an under-estimation of the actual
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with CPAP compared with those who were unable to
tolerate CPAP therapy at all. Another reason why may
have under-estimated the actual dierences between com-
pliant and non-compliant patients is the fact that a few of
the patients in the non-compliant group discontinued their
treatment 2–3 yr after CPAP treatment was initiated. This
may lead to a degree of misclassification, as the shortest
follow-up period for patients in the compliant group was 18
months. We also based our estimation of OSAS severity
exclusively on ODI and not on the frequency of apnoeas
and hypopnoeas. Despite these drawbacks, we believe that
this study yields information that is of value when it comes
to identifying patients who are at risk of not being able to
tolerate CPAP treatment.
There is little dispute that CPAP is the treatment of
choice for patients with severe OSAS. CPAP is also eective
in relieving daytime sleepiness and improving daytime
performance in mild OSAS (1,10,11) but, in accordance
with our results, other investigators have found that
patients with mild OSAS are more likely to discontinue
CPAP therapy than patients with a more severe OSAS
(1,6).
In our study, more than one-third of the patients who
discontinued CPAP therapy stated that nasal and phar-
yngeal side-eects were an important reason for stopping
treatment. Nasal side-eects are reported to occur in
15–45% of patients using CPAP (7). These side-eects
include nasal dripping, congestion and mucosal drying. The
mechanism behind these side-eects is not fully known, but
vasodilatation through the provocation of pressure-sensi-
tive mucosal receptors and mouth leak causing high
unidirectional nasal air flow may be two of the underlying
mechanisms (7,12). The results of our studies indicate that
this may be more common in elderly patients and is perhaps
related to a higher incidence of mucosal atrophy in elderly
patients. It is possible that some of the patients with side-
eects from the nose would have been able to continue with
CPAP if a heated air humidifier had been added (12,13). At
the time of the study, air humidifiers were, however, not
routinely prescribed at our clinic.
Uvulopalatopharyngoplasty (UPPP) was introduced as a
method of surgery for OSAS at the beginning of the 1980s
(14). Long-term follow-ups of OSAS patients undergoing
UPPP revealed, however, that many patients experiencing a
good short-term eect from the operation subsequently
relapse (9,15,16). These patients are then often referred for
CPAP therapy. Mortimore et al. found that UPPP increases
the mouth air leakage during CPAP therapy and postulated
that this could reduce tolerance and compliance during
CPAP therapy (17). In the present study we found that
patients who underwent UPPP discontinued CPAP more
frequently than patients who had not undergone this
procedure. The main reason for a higher discontinuation
rate in these kinds of patient were, however, that patients
who had undergone UPPP were less likely to find the CPAP
therapy eective. The reason for this may be that patients
who have undergone UPPP often report that the treatment
was symptomatically eective, even when night recordings
show a return of apnoeas or desaturations (9,15,16).In conclusion, patients with less severe OSAS are more
likely to discontinue CPAP treatment. The risk of
experiencing nasal and pharyngeal side-eects of such
severity that the patient stops using CPAP appears to
increase with age and patients who have undergone UPPP
are less likely to experience a clinical improvement after
being started on CPAP therapy.
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